|
|
Article: RHONE-POULENC RORER LAUNCHES DDAVP(TM) TABLETS FOR TREATMENT OF CENTRAL DIABETES INSIPIDUS (CDI)
- Article from:
- PR Newswire
- Article date:
- February 8, 1996
CopyrightCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
COLLEGEVILLE, Pa., Feb. 8 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) today announced that it has received Food and Drug Administration (FDA) clearance to market a tablet formulation of DDAVP (desmopressin acetate) for the treatment of central diabetes insipidus (CDI). DDAVP is a synthetic analog of vasopressin, an antidiuretic hormone affecting renal water conservation.
Currently, CDI can be treated with DDAVP in liquid form, delivered through a rhinal tube. Although the rhinal tube is a clinically effective treatment mode, DDAVP(TM) Tablets may offer a more convenient method of administration for those patients who must take the medication frequently.
...